[1]
American Cancer Society Cancer facts and figures 2015. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf (Accessed 15 July, 2019)
[2]
Fakiris, A.J.; McGarry, R.C.; Yiannoutsos, C.T. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int. J. Radiat. Oncol. Biol. Phys., 2009, 75, 677-682.
[3]
Hirsch, F.R.; Scagliotti, G.V.; Mulshine, J.L.; Kwon, R.; Curran, W.J., Jr; Wu, Y.L. Lung cancer: current therapies and new targeted treatments. Lancet, 2017, 389, 299-311.
[4]
Bütof Esther, R.; Troost, G.C. The role of functional imaging in lung cancer. Clin. Transl. Imaging, 2018, 6, 441-447.
[5]
Panunzio, A.; Sartori, P. Lung Cancer and Radiological Imaging. Curr. Radiopharm., 2019, 13, 238-242.
[7]
Castello, A.; Rossi, S.; Lopci, E. 18F-FDG PET/CT in restaging and evaluation of response to therapy in lung cancer: state of art. Curr. Radiopharm., 2019, 13, 228-237.
[8]
Evangelista, L.; Sepulcri, M.; Pasello, G. PET/CT and The Response to Immunotherapy In Lung Cancer. Curr. Radiopharm., 2019, 13, 177-184.
[9]
Filice, A.; Casali, M.; Ciammella, P.; Galaverni, M.; Fioroni, F.; Iotti, C.; Versari, A. Radiotherapy planning and Molecular Imaging in Lung Cancer. Curr. Radiopharm., 2019, 13, 204-217.
[10]
Crivellari, C.; Guerra, L. Respiratory Gating and the performance of PET/CT in pulmonary lesions. Curr. Radiopharm., 2019, 13, 218-227.
[11]
Spadafora, M.; Evangelista, L.; Fiordoro, S.; Porcaro, F.; Sicignano, M.; Mansi, L. The multicenter ITALIAN trial assess the performance of FDG-PET/CT related to pre-test cancer risk in patients with solitary pulmonary nodules and introduces a segmental thoracic diagnostic strategy. Curr. Radiopharm., 2019, 13, 243-248.